JP2024518844A5 - - Google Patents

Info

Publication number
JP2024518844A5
JP2024518844A5 JP2023571586A JP2023571586A JP2024518844A5 JP 2024518844 A5 JP2024518844 A5 JP 2024518844A5 JP 2023571586 A JP2023571586 A JP 2023571586A JP 2023571586 A JP2023571586 A JP 2023571586A JP 2024518844 A5 JP2024518844 A5 JP 2024518844A5
Authority
JP
Japan
Prior art keywords
seq
amino acid
acid sequence
antibody
antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023571586A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024518844A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/030189 external-priority patent/WO2022246154A2/en
Publication of JP2024518844A publication Critical patent/JP2024518844A/ja
Publication of JP2024518844A5 publication Critical patent/JP2024518844A5/ja
Pending legal-status Critical Current

Links

JP2023571586A 2021-05-20 2022-05-20 C1sに結合する抗体およびその使用 Pending JP2024518844A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163201952P 2021-05-20 2021-05-20
US63/201,952 2021-05-20
PCT/US2022/030189 WO2022246154A2 (en) 2021-05-20 2022-05-20 Antibodies that bind to c1s and uses thereof

Publications (2)

Publication Number Publication Date
JP2024518844A JP2024518844A (ja) 2024-05-07
JP2024518844A5 true JP2024518844A5 (enExample) 2025-05-28

Family

ID=84141843

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023571586A Pending JP2024518844A (ja) 2021-05-20 2022-05-20 C1sに結合する抗体およびその使用

Country Status (5)

Country Link
US (2) US12252550B2 (enExample)
EP (1) EP4340879A4 (enExample)
JP (1) JP2024518844A (enExample)
CN (1) CN117769434A (enExample)
WO (1) WO2022246154A2 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202426490A (zh) 2022-11-21 2024-07-01 美商黛安瑟斯醫療運營公司 結合c1s之抗體及其用途
KR20250158063A (ko) 2023-03-16 2025-11-05 젠자임 코포레이션 건식 연령-관련 황반 변성의 치료
WO2025129535A1 (en) * 2023-12-20 2025-06-26 Dianthus Therapeutics Opco, Inc. Pharmaceutical compositions comprising antibodies for treatment of c1s mediated disorders and methods of using the same
AU2024403267A1 (en) * 2023-12-20 2026-07-16 Dianthus Therapeutics Opco, Inc. Pharmaceutical compositions comprising antibodies for treatment of c1s mediated disorders and methods of using the same
TW202547886A (zh) * 2024-02-02 2025-12-16 美商黛安瑟斯醫療運營公司 用於治療c1s介導的疾病和病症的組成物、劑量和方法
US20250376511A1 (en) 2024-06-05 2025-12-11 Genzyme Corporation BINDING PROTEINS THAT TARGET aC1s, TfR, OR BOTH, AND COMPOSITIONS THEREOF
WO2026076063A2 (en) * 2024-10-01 2026-04-09 Dianthus Therapeutics Opco, Inc. Compositions, doses, and methods for treatment of c1s mediated diseases and disorders

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4447233A (en) 1981-04-10 1984-05-08 Parker-Hannifin Corporation Medication infusion pump
US4439196A (en) 1982-03-18 1984-03-27 Merck & Co., Inc. Osmotic drug delivery system
US4447224A (en) 1982-09-20 1984-05-08 Infusaid Corporation Variable flow implantable infusion apparatus
US4487603A (en) 1982-11-26 1984-12-11 Cordis Corporation Implantable microinfusion pump system
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4596556A (en) 1985-03-25 1986-06-24 Bioject, Inc. Hypodermic injection apparatus
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
EP0281604B1 (en) 1986-09-02 1993-03-31 Enzon Labs Inc. Single polypeptide chain binding molecules
US5260203A (en) 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
US4941880A (en) 1987-06-19 1990-07-17 Bioject, Inc. Pre-filled ampule and non-invasive hypodermic injection device assembly
US4790824A (en) 1987-06-19 1988-12-13 Bioject, Inc. Non-invasive hypodermic injection device
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US5312335A (en) 1989-11-09 1994-05-17 Bioject Inc. Needleless hypodermic injection device
US5064413A (en) 1989-11-09 1991-11-12 Bioject, Inc. Needleless hypodermic injection device
DE69233528T2 (de) 1991-11-25 2006-03-16 Enzon, Inc. Verfahren zur Herstellung von multivalenten antigenbindenden Proteinen
US5383851A (en) 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
US6005079A (en) 1992-08-21 1999-12-21 Vrije Universiteit Brussels Immunoglobulins devoid of light chains
DE69334275D1 (de) 1992-08-21 2009-05-20 Univ Bruxelles Immunoglobuline ohne Leichtkette
WO1994025591A1 (en) 1993-04-29 1994-11-10 Unilever N.V. PRODUCTION OF ANTIBODIES OR (FUNCTIONALIZED) FRAGMENTS THEREOF DERIVED FROM HEAVY CHAIN IMMUNOGLOBULINS OF $i(CAMELIDAE)
GB9818110D0 (en) 1998-08-19 1998-10-14 Weston Medical Ltd Needleless injectors and other devices
US6096002A (en) 1998-11-18 2000-08-01 Bioject, Inc. NGAS powered self-resetting needle-less hypodermic jet injection apparatus and method
EP1355919B1 (en) 2000-12-12 2010-11-24 MedImmune, LLC Molecules with extended half-lives, compositions and uses thereof
US8367805B2 (en) 2004-11-12 2013-02-05 Xencor, Inc. Fc variants with altered binding to FcRn
SG10201900183VA (en) * 2011-04-28 2019-05-30 Univ Leland Stanford Junior Identification of polynucleotides associated with a sample
ES2912396T3 (es) * 2012-11-02 2022-05-25 Bioverativ Usa Inc Anticuerpos anti-C1s del complemento y uso de los mismos
EP2997045A4 (en) 2013-05-15 2016-11-23 Annexon Inc ANTI-FACTOR C1S ANTIBODIES OF THE COMPLEMENT AND USES THEREOF
WO2015054670A1 (en) 2013-10-11 2015-04-16 Genentech, Inc. Nsp4 inhibitors and methods of use
EP4212175A1 (en) * 2015-04-06 2023-07-19 Bioverativ USA Inc. Humanized anti-c1s antibodies and methods of use thereof
CN106939047B (zh) * 2016-01-04 2021-08-31 江苏怀瑜药业有限公司 一种pd-l1抗体及其制备方法
IL326479A (en) 2016-10-12 2026-04-01 Bioverativ Usa Inc Anti-c1s antibodies and methods of use thereof
TWI780083B (zh) 2016-11-18 2022-10-11 丹麥商賽門弗鎮公司 抗pd-1抗體及組成物
SG11201907583TA (en) 2017-03-14 2019-09-27 Bioverativ Usa Inc Methods for treating complement-mediated diseases and disorders
EP4640703A3 (en) * 2017-11-14 2026-04-08 Chugai Seiyaku Kabushiki Kaisha Anti-c1s antibodies and methods of use
WO2022046888A1 (en) 2020-08-25 2022-03-03 Target Discovery Merger Sub II, LLC Sars-cov-2 associated antibody compositions and methods of use

Similar Documents

Publication Publication Date Title
JP7143452B2 (ja) CD47とSIRPaの相互作用を遮断できる抗体及びその応用
TWI757304B (zh) Lag-3抗體、其抗原結合片段及其醫藥用途
TWI821474B (zh) Cd3抗體及其藥物用途
US20220031842A1 (en) Lag-3 antibody pharmaceutical composition and use thereof
TWI788698B (zh) 抗pd-l1抗體及其應用
CN115397852B (zh) 工程化抗il-2抗体
KR20230113348A (ko) 항 SIRPα 항체 및 이의 용도
CN116490210A (zh) Cd70抗体及其应用
CN112969476A (zh) 多特异性蛋白分子
JP2020515277A5 (enExample)
TWI869542B (zh) 抗FcRn抗體、其抗原結合片段及其醫藥用途
WO2022242703A1 (zh) 抗msln抗体及其应用
JP2024024114A5 (enExample)
WO2023241656A1 (zh) 包含抗cldn18.2抗体的双特异性抗体、药物组合物及用途
WO2022218380A1 (zh) 靶向bcma的多特异性抗体
CN117940460A (zh) 双特异性抗原结合分子及其应用
US8974786B2 (en) Humanized antibodies to CA215
JP2024505195A5 (enExample)
CN111100204B (zh) 靶向cd20的抗体、其制备方法和应用
WO2022111559A1 (zh) 双特异性抗体及其用途
CN120040594B (zh) 一种靶向flt3基因编辑通用型car-t细胞的制备方法和应用
CN120383677B (zh) 靶向gp100/HLA-A2的高特异性TCR-mimic抗体及其制备方法
JP2022537142A5 (enExample)
WO2024041639A1 (en) Antibodies targeting tigit and uses thereof
CN115724985A (zh) 一种cdc平台抗体